Top

Clinical Reviews in Allergy & Immunology

Published in:

01-02-2020 | Systemic Sclerosis

Antinuclear Antibodies in Systemic Sclerosis: an Update

Authors: Anna Stochmal, Joanna Czuwara, Maria Trojanowska, Lidia Rudnicka

Published in: Clinical Reviews in Allergy & Immunology | Issue 1/2020

Abstract

Systemic sclerosis is an autoimmune disease characterized by fibrosis of skin and internal organs, vasculopathy, and dysregulation of immune system. A diagnostically important feature of immunological abnormalities in systemic sclerosis is the presence of circulating antinuclear antibodies, which may be detected in 90–95% of patients with either of the four main laboratory methods: immunofluorescence, enzyme-linked immunosorbent assay, immunodiffusion, and immunoblotting. There are several antinuclear antibodies specific for systemic sclerosis. These include antibodies against topoisomerase (anti-TOPO I), kinetochore proteins (ACA), RNA polymerase enzyme (anti-RNAP III), ribonuclear proteins (anti-U11/U12 RNP, anti-U1 RNP, anti-U3 RNP) and nucleolar antigens (anti-Th/To, anti-NOR 90, anti-Ku, antiRuvBL1/2, and anti-PM/Scl). Autoantibodies specific for systemic sclerosis have been linked to distinct clinical features. Therefore, detecting a particular antibody type is important in predicting a possible organ involvement and prognosis and may have an impact on monitoring and treatment.

Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390(10103):1685–1699. https://doi.org/10.1016/S0140-6736(17)30933-9 CrossRefPubMed

Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35(1):35–42. https://doi.org/10.1016/j.semarthrit.2005.03.005 CrossRefPubMed

Mierau R, Moinzadeh P, Riemekasten G, Melchers I, Meurer M, Reichenberger F, Buslau M, Worm M, Blank N, Hein R, Muller-Ladner U, Kuhn A, Sunderkotter C, Juche A, Pfeiffer C, Fiehn C, Sticherling M, Lehmann P, Stadler R, Schulze-Lohoff E, Seitz C, Foeldvari I, Krieg T, Genth E, Hunzelmann N (2011) Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther 13(5):R172. https://doi.org/10.1186/ar3495 CrossRefPubMedPubMedCentral

Mehra S, Walker J, Patterson K, Fritzler MJ (2013) Autoantibodies in systemic sclerosis. Autoimmun Rev 12(3):340–354. https://doi.org/10.1016/j.autrev.2012.05.011 CrossRefPubMed

van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Muller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum 65(11):2737–2747. https://doi.org/10.1002/art.38098 CrossRefPubMedPubMedCentral

Jordan S, Maurer B, Toniolo M, Michel B, Distler O (2015) Performance of the new ACR/EULAR classification criteria for systemic sclerosis in clinical practice. Rheumatology 54(8):1454–1458. https://doi.org/10.1093/rheumatology/keu530 CrossRefPubMed

Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, Cutolo M, Rongioletti F, Denton CP, Rudnicka L, Frasin LA, Smith V, Gabrielli A, Aberer E, Bagot M, Bali G, Bouaziz J, Braae Olesen A, Foeldvari I, Frances C, Jalili A, Just U, Kahari V, Karpati S, Kofoed K, Krasowska D, Olszewska M, Orteu C, Panelius J, Parodi A, Petit A, Quaglino P, Ranki A, Sanchez Schmidt JM, Seneschal J, Skrok A, Sticherling M, Sunderkotter C, Taieb A, Tanew A, Wolf P, Worm M, Wutte NJ, Krieg T (2017) European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin. Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. J Eur Acad Dermatol Venereol 31(9):1401–1424. https://doi.org/10.1111/jdv.14458 CrossRefPubMed

Krasowska D, Rudnicka L, Dańczak-Pazdrowska A, Chodorowska G, Woźniacka A, Lis-Święty A, Czuwara J, Maj J, Majewski S, Sysa-Jędrzejowska A, Wojas-Pelc A (2017) Systemic sclerosis—diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1: diagnosis and monitoring. Dermatol Rev 104(5):483–498. https://doi.org/10.5114/dr.2017.71214 CrossRef

Kranenburg P, van den Hombergh WM, Knaapen-Hans HK, van den Hoogen FH, Fransen J, Vonk MC (2016) Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study. Rheumatology (Oxford) 55(11):2001–2008. https://doi.org/10.1093/rheumatology/kew298 CrossRef

10.

Moinzadeh P, Nihtyanova SI, Howell K, Ong VH, Denton CP (2012) Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma. Clin Rev Allergy Immunol 43(3):249–255. https://doi.org/10.1007/s12016-012-8331-1 CrossRefPubMed

11.

Srivastava N, Hudson M, Tatibouet S, Wang M, Baron M, Fritzler MJ, (CSRG) CSRG (2015) Thinking outside the box—the associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect. Semin Arthritis Rheum 45(2):184–189. https://doi.org/10.1016/j.semarthrit.2015.04.009 CrossRefPubMed

12.

Claessens J, Belmondo T, De Langhe E, Westhovens R, Poesen K, Hue S, Blockmans D, Mahler M, Fritzler MJ, Bossuyt X (2018) Solid phase assays versus automated indirect immunofluorescence for detection of antinuclear antibodies. Autoimmun Rev 17:533–540. https://doi.org/10.1016/j.autrev.2018.03.002 CrossRefPubMed

13.

Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, Bossuyt X, Musset L, Cervera R, Plaza-Lopez A, Dias C, Sousa MJ, Radice A, Eriksson C, Hultgren O, Viander M, Khamashta M, Regenass S, Andrade LE, Wiik A, Tincani A, Ronnelid J, Bloch DB, Fritzler MJ, Chan EK, Garcia-De La Torre I, Konstantinov KN, Lahita R, Wilson M, Vainio O, Fabien N, Sinico RA, Meroni P, Shoenfeld Y (2014) International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 73(1):17–23. https://doi.org/10.1136/annrheumdis-2013-203863 CrossRefPubMed

14.

Meroni PL, Schur PH (2010) ANA screening: an old test with new recommendations. Ann Rheum Dis 69(8):1420–1422. https://doi.org/10.1136/ard.2009.127100 CrossRefPubMed

15.

Agmon-Levin N, Damoiseaux J, Shoenfeld Y (2014) Response to: ‘detection of antinuclear antibodies: added-value of solid phase assay?’ by Bossuyt and Fieuws. Ann Rheum Dis 73(3):e11. https://doi.org/10.1136/annrheumdis-2013-204797 CrossRefPubMed

16.

Hamaguchi Y (2010) Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol 37(1):42–53. https://doi.org/10.1111/j.1346-8138.2009.00762.x CrossRefPubMed

17.

Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LE (2011) Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 63(1):191–200. https://doi.org/10.1002/art.30084 CrossRefPubMed

18.

Stearns NA, Zhou S, Petri M, Binder SR, Pisetsky DS (2016) The use of poly-L-lysine as a capture agent to enhance the detection of antinuclear antibodies by ELISA. PLoS One 11(9):e0161818. https://doi.org/10.1371/journal.pone.0161818 CrossRefPubMedPubMedCentral

19.

Fritzler MJ (2012) Toward a new autoantibody diagnostic orthodoxy: understanding the bad, good and indifferent. Auto Immun Highlights 3(2):51–58. https://doi.org/10.1007/s13317-012-0030-7 CrossRefPubMedPubMedCentral

20.

Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, McDougal JS, Rothfield NF, Smeenk RJ, Takasaki Y, Wiik A, Wilson MR, Koziol JA (1997) Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum 40(9):1601–1611. https://doi.org/10.1002/1529-0131(199709)40:9<1601::AID-ART9>3.0.CO;2-T CrossRefPubMed

21.

Blaszczyk M, Beutner EH, Rogozinski T, Rzesa G, Jarzabek-Chorzelska M, Jablonska S, Chorzelski TP (1977) Substrate specificity of antinuclear antibodies in scleroderma. J Invest Dermatol 68(4):191–193CrossRefPubMed

22.

Murdjeva MA, Ryasheva NP, Draganov MM, Paunov LD (2011) A comparative study of immunological methods for determination of serum antinuclear antibodies. Folia Med (Plovdiv) 53(4):21–27CrossRef

23.

Fritzler MJ, Wiik A (2006) CHAPTER 72—autoantibody assays, testing, and standardization A2—Rose, Noel R. In: Mackay IR (ed) The autoimmune diseases, Fourth edn. Academic Press, St. Louis, pp 1011–1022. https://doi.org/10.1016/B978-012595961-2/50075-5 CrossRef

24.

de Almeida BF, Maria Eloi Santos S, Aparecida Ferreira G, Pedrosa W, Gradisse J, Cristina Costa L, Pretti Figueiredo Neves S (2016) Diagnostic evaluation of ELISA and chemiluminescent assays as alternative screening tests to indirect immunofluorescence for the detection of antibodies to cellular antigens. Am J Clin Pathol 145(3):323–331. https://doi.org/10.1093/ajcp/aqv083 CrossRef

25.

Op De Beeck K, Vermeersch P, Verschueren P, Westhovens R, Marien G, Blockmans D, Bossuyt X (2011) Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay. Autoimmun Rev 10(12):801–808. https://doi.org/10.1016/j.autrev.2011.06.005 CrossRef

26.

Mahler M, You D, Baron M, Taillefer SS, Hudson M, Fritzler MJ (2011) Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA. Clin Chim Acta 412(21):1937–1943. https://doi.org/10.1016/j.cca.2011.06.041 CrossRefPubMed

27.

Conrad K, Rober N, Andrade LE, Mahler M (2017) The clinical relevance of anti-DFS70 autoantibodies. Clin Rev Allergy Immunol 52(2):202–216. https://doi.org/10.1007/s12016-016-8564-5 CrossRefPubMed

28.

Hornbeck P (2001) Double-immunodiffusion assay for detecting specific antibodies. Curr Protoc Immunol Chapter 2:Unit 2.3. doi:https://doi.org/10.1002/0471142735.im0203s00 CrossRef

29.

Peterson LK, Jaskowski TD, Mayes MD, Tebo AE (2016) Detection of anti-U3-RNP/fibrillarin IgG antibodies by line immunoblot assay has comparable clinical significance to immunoprecipitation testing in systemic sclerosis. Immunol Res 64(2):483–488. https://doi.org/10.1007/s12026-015-8710-9 CrossRefPubMed

30.

Aksu G, Gulez N, Azarsiz E, Karaca N, Kutukculer N (2010) Determination of cut-off titers and agreement between immunofluorescence and immunoblotting methods for detecting antinuclear antibodies in children. J Clin Lab Anal 24(4):230–236. https://doi.org/10.1002/jcla.20391 CrossRefPubMedPubMedCentral

31.

Gonzalez C, Martin T, Arroyo T, Garcia-Isidoro M, Navajo JA, Gonzalez-Buitrago JM (1997) Comparison and variation of different methodologies for the detection of autoantibodies to nuclear antigens (ANA). J Clin Lab Anal 11(6):388–392CrossRefPubMed

32.

Nihtyanova SI, Denton CP (2010) Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 6(2):112–116. https://doi.org/10.1038/nrrheum.2009.238 CrossRefPubMed

33.

Kuwana M (2017) Circulating anti-nuclear antibodies in systemic sclerosis: utility in diagnosis and disease subsetting. J Nippon Med Sch 84(2):56–63. https://doi.org/10.1272/jnms.84.56 CrossRefPubMed

34.

Ma WT, Chang C, Gershwin ME, Lian ZX (2017) Development of autoantibodies precedes clinical manifestations of autoimmune diseases: a comprehensive review. J Autoimmun 83:95–112. https://doi.org/10.1016/j.jaut.2017.07.003 CrossRefPubMed

35.

Gunther J, Rademacher J, van Laar JM, Siegert E, Riemekasten G (2015) Functional autoantibodies in systemic sclerosis. Semin Immunopathol 37(5):529–542. https://doi.org/10.1007/s00281-015-0513-5 CrossRefPubMed

36.

Salazar GA, Assassi S, Wigley F, Hummers L, Varga J, Hinchcliff M, Khanna D, Schiopu E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Taillefer SS, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Molitor JA, Fritzler MJ, Segal BM, Al-Kassab F, Perry M, Yang J, Zamanian S, Reveille JD, Arnett FC, Pedroza C, Mayes MD (2015) Antinuclear antibody-negative systemic sclerosis. Semin Arthritis Rheum 44(6):680–686. https://doi.org/10.1016/j.semarthrit.2014.11.006 CrossRefPubMed

37.

Douvas AS, Achten M, Tan EM (1979) Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 254(20):10514–10522PubMed

38.

Poormoghim H, Moghadam AS, Moradi-Lakeh M, Jafarzadeh M, Asadifar B, Ghelman M, Andalib E (2013) Systemic sclerosis: demographic, clinical and serological features in 100 Iranian patients. Rheumatol Int 33(8):1943–1950. https://doi.org/10.1007/s00296-013-2668-5 CrossRefPubMed

39.

Reveille JD, Solomon DH (2003) Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 49(3):399–412. https://doi.org/10.1002/art.11113 CrossRefPubMed

40.

Hamaguchi Y, Kodera M, Matsushita T, Hasegawa M, Inaba Y, Usuda T, Kuwana M, Takehara K, Fujimoto M (2015) Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies. Arthritis Rheumatol 67(4):1045–1052. https://doi.org/10.1002/art.38994 CrossRefPubMed

41.

Cappelli S, Bellando Randone S, Camiciottoli G, De Paulis A, Guiducci S, Matucci-Cerinic M (2015) Interstitial lung disease in systemic sclerosis: where do we stand? Eur Respir Rev 24(137):411–419. https://doi.org/10.1183/16000617.00002915 CrossRefPubMed

42.

Hasegawa M (2016) Biomarker. In: Takehara K, Fujimoto M, Kuwana M (eds) Systemic sclerosis. Springer Japan, Tokyo, pp 211–229. https://doi.org/10.1007/978-4-431-55708-1_13 CrossRef

43.

Ho KT, Reveille JD (2003) The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 5(2):80–93CrossRefPubMedPubMedCentral

44.

Radic M, Martinovic Kaliterna D, Ljutic D (2006) The level of anti-topoisomerase I antibodies highly correlates with metacarpophalangeal and proximal interphalangeal joints flexion contractures in patients with systemic sclerosis. Clin Exp Rheumatol 24(4):407–412PubMed

45.

Bohelay G, Blaise S, Levy P, Claeys A, Baudot N, Cuny JF, Maillard H, Granel-Brocard F, Boye T, Lok C, Beneton N, Frances C, Senet P (2018) Lower-limb ulcers in systemic sclerosis: a multicentre retrospective case-control study. Acta Derm Venereol 98:677–682. https://doi.org/10.2340/00015555-2939 CrossRefPubMed

46.

Wirz EG, Jaeger VK, Allanore Y, Riemekasten G, Hachulla E, Distler O, Airo P, Carreira PE, Tikly M, Vettori S, Balbir Gurman A, Damjanov N, Muller-Ladner U, Distler J, Li M, Hausermann P, Walker UA (2016) Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Ann Rheum Dis 75(7):1285–1292. https://doi.org/10.1136/annrheumdis-2015-207271 CrossRefPubMed

47.

Rudnicka L, Czuwara J, Barusinska A, Nowicka U, Makiela B, Jablonska S (1996) Implications for the use of topoisomerase I inhibitors in treatment of patients with systemic sclerosis. Ann N Y Acad Sci 803:318–320CrossRefPubMed

48.

Saito A, Muro Y, Sugiura K, Akiyama M (2013) Low prevalence of autoantibodies to CENP-H, -I, -K, -L, -M, -N, -T and -U in a Japanese cohort of anti-centromere positive samples. Immunopharmacol Immunotoxicol 35(1):57–63. https://doi.org/10.3109/08923973.2012.733707 CrossRefPubMed

49.

Gelber AC, Pillemer SR, Baum BJ, Wigley FM, Hummers LK, Morris S, Rosen A, Casciola-Rosen L (2006) Distinct recognition of antibodies to centromere proteins in primary Sjogren’s syndrome compared with limited scleroderma. Ann Rheum Dis 65(8):1028–1032. https://doi.org/10.1136/ard.2005.046003 CrossRefPubMedPubMedCentral

50.

Lleo A, Marzorati S, Anaya JM, Gershwin ME (2017) Primary biliary cholangitis: a comprehensive overview. Hepatol Int 11(6):485–499. https://doi.org/10.1007/s12072-017-9830-1 CrossRefPubMed

51.

Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Muller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group Database. Ann Rheum Dis 66(6):754–763. https://doi.org/10.1136/ard.2006.062901 CrossRefPubMedPubMedCentral

52.

Heijnen IA, Foocharoen C, Bannert B, Carreira PE, Caporali R, Smith V, Kumanovics G, Becker MO, Vanthuyne M, Simsek I, Bocelli-Tyndall C, Walker UA (2013) Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study. Clin Exp Rheumatol 31(2 Suppl 76):96–102PubMed

53.

Sobanski V, Dauchet L, Lefevre G, Lambert M, Morell-Dubois S, Sy T, Hachulla E, Hatron PY, Launay D, Dubucquoi S (2014) Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: new data from a French cohort and a systematic review and meta-analysis. Arthritis Rheumatol 66(2):407–417. https://doi.org/10.1002/art.38219 CrossRefPubMed

54.

Denton CP, Steen V (2012) Scleroderma renal crisis. In: Varga J, Denton CP, Wigley FM (eds) Scleroderma: from pathogenesis to comprehensive management. Springer US, Boston, pp 361–371. https://doi.org/10.1007/978-1-4419-5774-0_29 CrossRef

55.

Ghrenassia E, Avouac J, Khanna D, Derk CT, Distler O, Suliman YA, Airo P, Carreira PE, Foti R, Granel B, Berezne A, Cabane J, Ingegnoli F, Rosato E, Caramaschi P, Hesselstrand R, Walker UA, Alegre-Sancho JJ, Zarrouk V, Agard C, Riccieri V, Schiopu E, Gladue H, Steen VD, Allanore Y (2014) Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study. J Rheumatol 41(1):99–105. https://doi.org/10.3899/jrheum.130386 CrossRefPubMed

56.

Lazzaroni MG, Cavazzana I, Colombo E, Dobrota R, Hernandez J, Hesselstrand R, Varju C, Nagy G, Smith V, Caramaschi P, Riccieri V, Hachulla E, Balbir-Gurman A, Chatelus E, Romanowska-Prochnicka K, Araujo AC, Distler O, Allanore Y, Airo P (2017) Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening. J Rheumatol 44(5):639–647. https://doi.org/10.3899/jrheum.160817 CrossRefPubMed

57.

Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L (2010) Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 62(9):2787–2795. https://doi.org/10.1002/art.27549 CrossRefPubMedPubMedCentral

58.

Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, Boin F, Fava A, Thoburn C, Kinde I, Jiao Y, Papadopoulos N, Kinzler KW, Vogelstein B, Rosen A (2014) Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343(6167):152–157. https://doi.org/10.1126/science.1246886 CrossRefPubMed

59.

Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger TA Jr (2009) Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 60(4):1112–1118. https://doi.org/10.1002/art.24409 CrossRefPubMed

60.

Steen V (2003) Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 62(2):97–99CrossRefPubMedPubMedCentral

61.

Nishimagi E, Tochimoto A, Kawaguchi Y, Satoh T, Kuwana M, Takagi K, Ichida H, Kanno T, Soejima M, Baba S, Kamatani N, Hara M (2007) Characteristics of patients with early systemic sclerosis and severe gastrointestinal tract involvement. J Rheumatol 34(10):2050–2055PubMed

62.

Maddison PJ (2000) Mixed connective tissue disease: overlap syndromes. Baillieres Best Pract Res Clin Rheumatol 14(1):111–124. https://doi.org/10.1053/berh.1999.0080 CrossRefPubMed

63.

Moinzadeh P, Aberer E, Ahmadi-Simab K, Blank N, Distler JH, Fierlbeck G, Genth E, Guenther C, Hein R, Henes J, Herich L, Herrgott I, Koetter I, Kreuter A, Krieg T, Kuhr K, Lorenz HM, Meier F, Melchers I, Mensing H, Mueller-Ladner U, Pfeiffer C, Riemekasten G, Sardy M, Schmalzing M, Sunderkoetter C, Susok L, Tarner IH, Vaith P, Worm M, Wozel G, Zeidler G, Hunzelmann N (2015) Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 74(4):730–737. https://doi.org/10.1136/annrheumdis-2013-204487 CrossRefPubMed

64.

Steen V, Domsic RT, Lucas M, Fertig N, Medsger TA Jr (2012) A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum 64(9):2986–2994. https://doi.org/10.1002/art.34482 CrossRefPubMedPubMedCentral

65.

Ihn H, Yamane K, Yazawa N, Kubo M, Fujimoto M, Sato S, Kikuchi K, Tamaki K (1999) Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis. Clin Exp Immunol 117(2):383–387CrossRefPubMedPubMedCentral

66.

Sobanski V, Giovannelli J, Lynch BM, Schreiber BE, Nihtyanova SI, Harvey J, Handler CE, Denton CP, Coghlan JG (2016) Characteristics and survival of anti-U1 RNP antibody-positive patients with connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheumatol 68(2):484–493. https://doi.org/10.1002/art.39432 CrossRefPubMed

67.

Van Eenennaam H, Vogelzangs JH, Lugtenberg D, Van Den Hoogen FH, Van Venrooij WJ, Pruijn GJ (2002) Identity of the RNase MRP- and RNase P-associated Th/To autoantigen. Arthritis Rheum 46(12):3266–3272. https://doi.org/10.1002/art.10673 CrossRefPubMed

68.

Okano Y, Medsger TA Jr (1990) Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 33(12):1822–1828CrossRefPubMed

69.

Mahler M, Satoh M, Hudson M, Baron M, Chan JY, Chan EK, Wick J, Fritzler MJ (2014) Autoantibodies to the Rpp25 component of the Th/To complex are the most common antibodies in patients with systemic sclerosis without antibodies detectable by widely available commercial tests. J Rheumatol 41(7):1334–1343. https://doi.org/10.3899/jrheum.131450 CrossRefPubMed

70.

Mitri GM, Lucas M, Fertig N, Steen VD, Medsger TA Jr (2003) A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 48(1):203–209. https://doi.org/10.1002/art.10760 CrossRefPubMed

71.

Jimenez-Garcia LF, Rothblum LI, Busch H, Ochs RL (1989) Nucleologenesis: use of non-isotopic in situ hybridization and immunocytochemistry to compare the localization of rDNA and nucleolar proteins during mitosis. Biol Cell 65(3):239–246CrossRefPubMed

72.

Chan EK, Imai H, Hamel JC, Tan EM (1991) Human autoantibody to RNA polymerase I transcription factor hUBF. Molecular identity of nucleolus organizer region autoantigen NOR-90 and ribosomal RNA transcription upstream binding factor. J Exp Med 174(5):1239–1244CrossRefPubMed

73.

Imai H, Fritzler MJ, Neri R, Bombardieri S, Tan EM, Chan EK (1994) Immunocytochemical characterization of human NOR-90 (upstream binding factor) and associated antigens reactive with autoimmune sera. Two MR forms of NOR-90/hUBF autoantigens. Mol Biol Rep 19(2):115–124CrossRefPubMed

74.

Villalta D, Imbastaro T, Di Giovanni S, Lauriti C, Gabini M, Turi MC, Bizzaro N (2012) Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev 12(2):114–120. https://doi.org/10.1016/j.autrev.2012.07.005 CrossRefPubMed

75.

Fujii T, Mimori T, Akizuki M (1996) Detection of autoantibodies to nucleolar transcription factor NOR 90/hUBF in sera of patients with rheumatic diseases, by recombinant autoantigen-based assays. Arthritis Rheum 39(8):1313–1318CrossRefPubMed

76.

Imai H, Ochs RL, Kiyosawa K, Furuta S, Nakamura RM, Tan EM (1992) Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol 140(4):859–870PubMedPubMedCentral

77.

Dagher JH, Scheer U, Voit R, Grummt I, Lonzetti L, Raymond Y, Senecal JL (2002) Autoantibodies to NOR 90/hUBF: longterm clinical and serological followup in a patient with limited systemic sclerosis suggests an antigen driven immune response. J Rheumatol 29(7):1543–1547PubMed

78.

Tarn WY, Steitz JA (1996) A novel spliceosome containing U11, U12, and U5 snRNPs excises a minor class (AT-AC) intron in vitro. Cell 84(5):801–811CrossRefPubMed

79.

Fertig N, Domsic RT, Rodriguez-Reyna T, Kuwana M, Lucas M, Medsger TA Jr, Feghali-Bostwick CA (2009) Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum 61(7):958–965. https://doi.org/10.1002/art.24586 CrossRefPubMedPubMedCentral

80.

Brouwer R, Vree Egberts WT, Hengstman GJ, Raijmakers R, van Engelen BG, Seelig HP, Renz M, Mierau R, Genth E, Pruijn GJ, van Venrooij WJ (2002) Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis Res 4(2):134–138. https://doi.org/10.1186/ar389 CrossRefPubMed

81.

Brouwer R, Hengstman GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A, Grondal G, Hietarinta M, Isenberg D, Kalden JR, Lundberg I, Moutsopoulos H, Roux-Lombard P, Vencovsky J, Wikman A, Seelig HP, van Engelen BG, van Venrooij WJ (2001) Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 60(2):116–123CrossRefPubMedPubMedCentral

82.

Gunawardena H (2017) The clinical features of myositis-associated autoantibodies: a review. Clin Rev Allergy Immunol 52(1):45–57. https://doi.org/10.1007/s12016-015-8513-8 CrossRefPubMed

83.

D'Aoust J, Hudson M, Tatibouet S, Wick J, Mahler M, Baron M, Fritzler MJ (2014) Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheumatol 66(6):1608–1615. https://doi.org/10.1002/art.38428 CrossRefPubMed

84.

Mimori T (2002) Clinical significance of anti-Ku autoantibodies—a serologic marker of overlap syndrome? Intern Med 41(12):1096–1098CrossRefPubMed

85.

Cavazzana I, Ceribelli A, Quinzanini M, Scarsi M, Airo P, Cattaneo R, Franceschini F (2008) Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. Lupus 17(8):727–732. https://doi.org/10.1177/0961203308089442 CrossRefPubMed

86.

Rozman B, Cucnik S, Sodin-Semrl S, Czirjak L, Varju C, Distler O, Huscher D, Aringer M, Steiner G, Matucci-Cerinic M, Guiducci S, Stamenkovic B, Stankovic A, Kveder T (2008) Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study. Ann Rheum Dis 67(9):1282–1286. https://doi.org/10.1136/ard.2007.073981 CrossRefPubMed

87.

Hoa S, Hudson M, Troyanov Y, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Wang M, Baron M, Fritzler MJ (2016) Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations. Medicine (Baltimore) 95(35):e4713. https://doi.org/10.1097/md.0000000000004713 CrossRef

88.

Cavazzana I, Fredi M, Taraborelli M, Quinzanini M, Tincani A, Franceschini F (2013) A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies. Clin Exp Rheumatol 31(2 Suppl 76):118–121PubMed

89.

Shah AA, Casciola-Rosen L, Rosen A (2015) Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol 67(2):317–326. https://doi.org/10.1002/art.38928 CrossRefPubMedPubMedCentral

90.

Zaarur N, Xu X, Lestienne P, Meriin AB, McComb M, Costello CE, Newnam GP, Ganti R, Romanova NV, Shanmugasundaram M, Silva ST, Bandeiras TM, Matias PM, Lobachev KS, Lednev IK, Chernoff YO, Sherman MY (2015) RuvbL1 and RuvbL2 enhance aggresome formation and disaggregate amyloid fibrils. EMBO J 34(18):2363–2382. https://doi.org/10.15252/embj.201591245 CrossRefPubMedPubMedCentral

91.

Pauling JD, Salazar G, Lu H, Betteridge ZE, Assassi S, Mayes MD, McHugh NJ (2018) Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis. Rheumatology (Oxford) 57(4):712–717. https://doi.org/10.1093/rheumatology/kex458 CrossRef

92.

Kaji K, Fertig N, Medsger TA Jr, Satoh T, Hoshino K, Hamaguchi Y, Hasegawa M, Lucas M, Schnure A, Ogawa F, Sato S, Takehara K, Fujimoto M, Kuwana M (2014) Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement. Arthritis Care Res (Hoboken) 66(4):575–584. https://doi.org/10.1002/acr.22163 CrossRef

93.

Betteridge ZE, Woodhead F, Lu H, Shaddick G, Bunn CC, Denton CP, Abraham DJ, du Bois RM, Lewis M, Wells AU, McHugh NJ (2016) Brief report: anti-eukaryotic initiation factor 2B autoantibodies are associated with interstitial lung disease in patients with systemic sclerosis. Arthritis Rheumatol 68(11):2778–2783. https://doi.org/10.1002/art.39755 CrossRefPubMed

94.

Pavitt GD (2005) eIF2B, a mediator of general and gene-specific translational control. Biochem Soc Trans 33(Pt 6):1487–1492. https://doi.org/10.1042/bst20051487 CrossRefPubMed

95.

Fattal I, Shental N, Molad Y, Gabrielli A, Pokroy-Shapira E, Oren S, Livneh A, Langevitz P, Pauzner R, Sarig O, Gafter U, Domany E, Cohen IR (2014) Epstein-Barr virus antibodies mark systemic lupus erythematosus and scleroderma patients negative for anti-DNA. Immunology 141(2):276–285. https://doi.org/10.1111/imm.12200 CrossRefPubMedPubMedCentral

Title: Antinuclear Antibodies in Systemic Sclerosis: an Update
Authors: Anna Stochmal
Joanna Czuwara
Maria Trojanowska
Lidia Rudnicka
Publication date: 01-02-2020
Publisher: Springer US
Keywords: Systemic Sclerosis
Scleroderma
Published in: Clinical Reviews in Allergy & Immunology / Issue 1/2020
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-018-8718-8

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Regulatory T Cell Plasticity and Stability and Autoimmune Diseases

Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis

Standardization of Autoantibody Testing in Autoimmune Hepatitis

Resolvins: Emerging Players in Autoimmune and Inflammatory Diseases